Objective
High-risk neuroblastoma accounts for 15% of cancer related-deaths in children. Half of the >1500 patients yearly diagnosed with neuroblastoma in the EU have high-risk disease, which will relapse or progress in half these cases after first-line treatment. Relapsed neuroblastoma is aggressive and often therapy-resistant. Monitoring for disease relapse and therapy response is crucial for the survival chance of these patients. The current standard-of-care for monitoring are imaging technologies and bone marrow assessment, which are costly, invasive and a burden for children, who often require anesthesia. These drawbacks limit how often is monitored. More sensitive, less invasive and less toxic monitoring techniques are needed. The mutational spectrum often changes in recurring tumors, which may explain therapy resistance and provide additional druggable targets. Imaging, however, provides no information about molecular characteristics. Liquid biopsy tests are minimally invasive, allow frequent sampling and sensitively detect tumor molecular markers in tumor-derived DNA and messenger RNA circulating in peripheral blood. MONALISA aims to close existing gaps and establish liquid biopsies as standard-of-care to monitor relapsed/refractory neuroblastoma, as a blueprint for other pediatric cancers. Reliable, early assessment of molecular progression or relapse is the main aim of the pragmatic randomized clinical trial proposed in MONALISA. We develop a digital decision support tool to help oncologists use the new monitoring and apply patient-reported outcomes to integrate patient viewpoints and assess the effect of minimally invasive, liquid biopsy diagnostics on quality of life. We will establish whether events can be detected earlier using liquid biopsy monitoring, and whether better overall survival is enabled by earlier diagnosis and treatment interventions. This essential step towards personalized medicine will support reliable disease monitoring under treatment. “This action is part of the Cancer Mission cluster of projects on ‘‘Diagnostics and Treatment (diagnostics).”
Fields of science
Keywords
Programme(s)
- HORIZON.2.1 - Health Main Programme
Topic(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
1200 Bruxelles / Brussel
Belgium
See on map
Participants (20)
1090 Wien
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
1090 Wien
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
10117 Berlin
See on map
3001 Leuven
See on map
9000 Gent
See on map
08035 Barcelona
See on map
1081 HV Amsterdam
See on map
94805 Villejuif
See on map
10561 Athina
See on map
115 27 ATHINA
See on map
6020 Innsbruck
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
75231 Paris
See on map
6020 Innsbruck
See on map
3584CS Utrecht
See on map
72074 Tuebingen
See on map
D08 HP97 Dublin
See on map
1210 Wien
See on map
150 06 Praha 5
See on map
1090 Wien
See on map
16147 Genova
See on map
Partners (4)
9052 ZWIJNAARDE - GENT
See on map
LS2 9JT Leeds
See on map
WC1N 1AZ London
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
SW7 3RP London
See on map